Abnormal oncogene activation by fusion of anaplastic lymphoma kinase (ALK) [5,6], C-ros oncogene 1 (ROS1) [7,8], and Ret proto-oncogene (RET) [9,10] has been identified in NSCLC [11]. This evidence concerns the gene ALK and non-small cell lung carcinoma.